Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/43579
Title: The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
Authors: Mari, Jair de Jesus [UNIFESP]
Lima, Mauricio Silva de [UNIFESP]
Costa, Anna Maria Niccolai [UNIFESP]
Alexandrino, Neusa
Rodrigues-Filho, Salomao
Oliveira, Irismar Reis de
Tollefson, Gary D.
Universidade Federal de São Paulo (UNIFESP)
Fed Univ Pelotas
Catholic Univ Pelotas
Hosp Anna Rech
Pax Clin Psiquiatrica Goiania
Universidade Federal da Bahia (UFBA)
Keywords: schizophrenia
Tardive dyskinesia
randomized controlled trial
olanzapine
typical antipsychotic
Issue Date: 1-Dec-2004
Publisher: Dr Dietrich Steinkopff Verlag
Citation: European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004.
Abstract: Aims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.
URI: http://repositorio.unifesp.br/11600/43579
ISSN: 0940-1334
Other Identifiers: http://dx.doi.org/10.1007/s00406-004-0514-1
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.